This Article Full Text Full Text (PDF) All Versions of this Article: 149/4/1987    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Google Scholar Articles by Page, S. T. Articles by Matsumoto, A. M. PubMed PubMed Citation Articles by Page, S. T. Articles by Matsumoto, A. M.

Tissue Selectivity of the Anabolic Steroid, 19-Nor-4-Androstenediol-3β,17β-Diol in Male Sprague Dawley Rats: Selective Stimulation of Muscle Mass and Bone Mineral Density Relative to Prostate Mass

Department of Medicine (S.T.P., A.M.M.), University of Washington School of Medicine, Seattle, Washington 98195; Geriatric Research, Education and Clinical Center (B.T.M., A.M.M.), Veterans Administration Puget Sound Health Care System, Seattle, Washington 98108; and Office of Diversion Control (J.M.T.), Drug Enforcement Administration, Department of Justice, Arlington, Virginia 22202

Address all correspondence and requests for reprints to: Stephanie T. Page, M.D., Ph.D., Assistant Professor, Division of Endocrinology and Metabolism, Department of Medicine, University of Washington Medical Center, 1959 NE Pacific, Box 356426, Seattle, Washington 98195. E-mail: page{at}u.washington.edu.

Stimulation of prostate growth is a major concern with testosterone therapy in older hypogonadal men. As a result, nonsteroidal selective androgen receptor modulators with anabolic activity but less prostate stimulation are being developed. Anabolic steroids might exhibit similar tissue selectivity. We hypothesized the anabolic steroid 19-nor-4-androstenediol-3β,17β-diol (3β,19-NA) would increase muscle, lean body mass (LBM), and bone mineral density (BMD) with little stimulation of prostate growth. Male Sprague Dawley rats were implanted with SILASTIC brand (Dow Corning, Midland, MI) capsules containing 3β,19-NA (4, 8, or 16 cm), dihydrotestosterone (DHT) (8 cm), 19-nortestosterone (16 cm), or four empty capsules after undergoing either a sham operation (intact) or orchidectomy (ORX). Serum gonadotropins, measured after 4, 8, or 24 wk of treatment, were significantly lower in 3β,19-NA-treated vs. untreated, intact, and ORX rats (P < 0.05), and testosterone was lowered by 3β,19-NA-treatment of intact animals. LBM and BMD were assessed after 20 wk, and 4 wk later, rats were killed for levator ani muscle and prostate weights. Compared with ORX rats, 3β,19-NA-treated rats had dose-dependent higher levator ani muscle weights, LBM, and BMD, which were similar to intact and DHT-treated rats at the highest 3β,19-NA dose. In contrast, prostate weights in all 3β,19-NA-treated groups were similar to ORX rats and lower than intact and DHT- and 19-nortestosterone-treated rats even at the highest 3β,19-NA dose. In summary, 3β,19-NA increases muscle and bone mass without significant stimulation of prostate growth, suggesting it may have some properties of a steroidal selective androgen receptor modulator. Anabolic steroids such as 3β,19-NA should be studied further to determine their mechanisms of tissue selectivity and effects in men.